Yanli Xing
Yanli Xing has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Anthony C. Faber
VCU Philips Institute, Virginia Commonwealth University School of Dentistry and Massey Comprehensive Cancer Center, Richmond, VA 23298, USA
1 shared publication - Bin Hu
Virginia Commonwealth University 1 Richmond, VA
1 shared publication - Jamie M. Slaughter
Virginia Commonwealth University 2
1 shared publication - Jane Roberts
Virginia Commonwealth University 1 Richmond, VA
1 shared publication - Jenna Saleh
Virginia Commonwealth University 2
1 shared publication - Jennifer E. Koblinski
Massey Cancer Center, Virginia Commonwealth University, Richmond, USA
1 shared publication
Latest Publications
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS-mutant neuroblastoma
Neuroblastoma (NB) is the most common extracranial solid tumor in children. Patients with relapsed or refractory (R/R) high-risk (HR) NB exhibit poor outcomes despite intensive multimodal therapy. Although MAPK pathway activation is prominent in HRNB, FDA-approved MEK inhibitors and KRAS G12C inhibitors have shown limited preclinical single-agent activity in HRNB. Daraxonrasib (RMC-6236), a potent and selective RAS(ON) inhibitor, has demonstrated activity in preclinical models and early-phase clinical trials of RAS-mutant adult cancers. A subset of R/R HRNB tumors harbors diverse RAS mutations, providing a rationale for investigating RMC-6236 in this setting. Here, we evaluated the therapeutic efficacy and effects of oncogenic signaling modulation of RMC-6236 across NB models with RAS pathway activation. As a single agent, RMC-6236 significantly reduced cell viability, suppressed downstream MAPK signaling, increased expression of the MAPK pathway effector BIM, and induced cell death in RAS-mutant NB models as well as in NF1-mutant NB models. In vivo, RMC-6236 demonstrated on-target activity, significantly inhibited tumor growth, and extended survival in RAS-mutant HRNB mouse models. Furthermore, RMC-6236 induced BIM upregulation and promoted BIM:BCL-2 complexes in RAS-mutant NB. As such, the BCL-2 inhibitor venetoclax further potentiated RMC-6236-mediated killing by disrupting these complexes. Together, these findings identify RMC-6236 as a promising targeted therapy for RAS-mutant NB and support its clinical investigation, both as a single agent and in combination with venetoclax, in this patient population.
- 16 November 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
Open AccessDaraxonrasib (RMC-6236) is an effective targeted therapy for RAS-mutant neuroblastoma
Neuroblastoma (NB) is the most common extracranial solid tumor in children. Patients with relapsed or refractory (R/R) high-risk (HR) NB exhibit poor outcomes despite intensive multimodal therapy. Although MAPK pathway activation is prominent in HRNB, FDA-approved MEK inhibitors and KRAS G12C inhibitors have shown limited preclinical single-agent activity in HRNB. Daraxonrasib (RMC-6236), a potent and selective RAS(ON) inhibitor, has demonstrated activity in preclinical models and early-phase clinical trials of RAS-mutant adult cancers. A subset of R/R HRNB tumors harbors diverse RAS mutations, providing a rationale for investigating RMC-6236 in this setting. Here, we evaluated the therapeutic efficacy and effects of oncogenic signaling modulation of RMC-6236 across NB models with RAS pathway activation. As a single agent, RMC-6236 significantly reduced cell viability, suppressed downstream MAPK signaling, increased expression of the MAPK pathway effector BIM, and induced cell death in RAS-mutant NB models as well as in NF1-mutant NB models. In vivo, RMC-6236 demonstrated on-target activity, significantly inhibited tumor growth, and extended survival in RAS-mutant HRNB mouse models. Furthermore, RMC-6236 induced BIM upregulation and promoted BIM:BCL-2 complexes in RAS-mutant NB. As such, the BCL-2 inhibitor venetoclax further potentiated RMC-6236-mediated killing by disrupting these complexes. Together, these findings identify RMC-6236 as a promising targeted therapy for RAS-mutant NB and support its clinical investigation, both as a single agent and in combination with venetoclax, in this patient population.